Effect of a Pharmaceutical Intervention on the Level of Control of the Asthmatic Patient
Completed
- Conditions
- Asthma
- Registration Number
- NCT01085474
- Lead Sponsor
- AstraZeneca
- Brief Summary
Measurement of disease control, treatment adherence and patient knowledge of his/her medication in patients that are receiving a pharmaceutical intervention compared with those patients who receive regular pharmaceutical care.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 384
Inclusion Criteria
- Patients who have given their informed consent and expressed interest in participating in the study
- Asthmatic Patients
Exclusion Criteria
- Patients with communication difficulties.
- Persons who obtain symbicort but not for their own use.
- Patients with other major diseases: Heart problems, COPD, EMPHYSEMA, lung cancer, AIDS.
- Patients with a respiratory infection.
- Patients with seasonal asthma.
- Pregnant women
- Patients who have previously participated in a health education study in asthma.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluate the effect of the pharmaceutical intervention on the disease control, treatment adherence and patient knowledge of his/her medication using the MEF, treatment adherence and patient knowledge of the medication indicators. First a Pilot in 3 months and then the final study in 6 months
- Secondary Outcome Measures
Name Time Method Compare disease control in patients who know their medication and those who doesn't. First a Pilot in 3 months and then the final study in 6 months Compare disease control in patients who comply with their medication with those who doesn't. First a Pilot in 3 months and then the final study in 6 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie improved asthma control in NCT01085474 intervention group?
How does the pharmaceutical intervention in NCT01085474 compare to standard asthma therapies in effectiveness?
Are there specific biomarkers associated with better outcomes in NCT01085474 asthma intervention study?
What adverse events were observed in NCT01085474 and how do they compare to AstraZeneca's asthma medications?
What combination therapies or competitor drugs show similar asthma control improvements as NCT01085474 intervention?
Trial Locations
- Locations (2)
Research Site
🇪🇸Madrid, Spain
Malaga
🇪🇸Malaga, Spain
Research Site🇪🇸Madrid, Spain